Drs. Wassim Mchayleh & Komal Jhaveri: EMBER-3 Trial Insights

Drs. Wassim Mchayleh and Komal Jhaveri discuss the EMBER-3 trial evaluating the oral SERD imlunestrant in patients with ER-positive metastatic breast cancer who progressed after aromatase inhibitor therapy, with or without prior CDK4/6 inhibition. The study demonstrated improved progression-free survival versus standard endocrine therapy in ESR1-mutant tumors, leading to approval of imlunestrant monotherapy for this population. They also highlight emerging data for the imlunestrant plus abemaciclib combination, which shows encouraging efficacy but has not yet received regulatory approval.